<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03508011</url>
  </required_header>
  <id_info>
    <org_study_id>IMP4297-2016-CN01</org_study_id>
    <nct_id>NCT03508011</nct_id>
  </id_info>
  <brief_title>A Study of IMP4297 in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Impact Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Impact Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, first-in-human, open-label, dose-escalation study of IMP4297 administered&#xD;
      orally once every day to patients with advanced solid tumors for whom standard therapy either&#xD;
      does not exist or has proven to be ineffective or intolerable. Patients with advanced breast&#xD;
      cancer, ovarian cancer or prostate cancer are preferred. There are two stages to this study:&#xD;
      a dose-escalation stage and a dose-expansion stage.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 23, 2017</start_date>
  <completion_date type="Actual">December 16, 2020</completion_date>
  <primary_completion_date type="Actual">December 16, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The AEs (adverse event) of single and multiple doses of IMP4297 administered to participants with advanced solid tumors.</measure>
    <time_frame>Each visit after IMP4297 administrated (through study completion, an average of 10 months)</time_frame>
    <description>Evaluate the TEAE (treatment-emergent adverse event) of IMP4297</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The maximum tolerated dose (MTD) and evaluate the dose limiting toxicities (DLTs) of IMP4297</measure>
    <time_frame>Within 28 days after IMP4297 administrated</time_frame>
    <description>Evaluate DLT and determine the MTD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve [AUClast, AUCINF]</measure>
    <time_frame>Within 7 days after firstly single dose administrated</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve [AUClast, AUCINF]</measure>
    <time_frame>Within 16 days after first dose administrated in multiple dose cycle 1 (total 21 days in one cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>Within 7 days after firstly single dose administrated</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>Within 16 days after first dose administrated in multiple dose cycle 1 (total 21 days in one cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time at which Cmax occurred (Tmax)</measure>
    <time_frame>Within 7 days after firstly single dose administrated</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time at which Cmax occurred (Tmax)</measure>
    <time_frame>Within 16 days after first dose administrated in multiple dose cycle 1 (total 21 days in one cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Concentrations (Ctrough)</measure>
    <time_frame>Within 7 days after firstly single dose administrated</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Concentrations (Ctrough)</measure>
    <time_frame>Within 16 days after first dose administrated in multiple dose cycle 1 (total 21 days in one cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL/F)</measure>
    <time_frame>Within 7 days after firstly single dose administrated</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL/F)</measure>
    <time_frame>Within 16 days after first dose administrated in multiple dose cycle 1 (total 21 days in one cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vd/F)</measure>
    <time_frame>Within 7 days after firstly single dose administrated</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vd/F)</measure>
    <time_frame>Within 16 days after first dose administrated in multiple dose cycle 1 (total 21 days in one cycle)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Advanced Solid Tumours</condition>
  <condition>Breast Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>IMP4297</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMP4297</intervention_name>
    <description>The dose levels will be escalated following a modified 3+3 dose escalation scheme.</description>
    <arm_group_label>IMP4297</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed Informed Consent Form&#xD;
&#xD;
          2. 18 Years to 70 Years (including 18 and 75 years)&#xD;
&#xD;
          3. Histologically or cytologically documented disease; incurable, advanced solid&#xD;
             malignancy that has progressed on, or failed to respond to, at least one prior&#xD;
             systemic therapy&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group performance status of 0 or 1&#xD;
&#xD;
          5. In the dose expansion stage, patients with BRCA (breast carcinoma) mutation will be&#xD;
             enrolled. Patients with breast cancer, ovarian cancer and prostate cancer are&#xD;
             preferred.&#xD;
&#xD;
          6. In the dose escalation phase, at least one assessable lesion according to the RECIST&#xD;
             1.1 standard; In the dose expansion phase, at least one measurable lesion according to&#xD;
             RECIST 1.1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inadequate hematologic and organ function, defined by the following (hematologic&#xD;
             parameters must be assessed ≥14 days after a prior treatment, if any):&#xD;
&#xD;
               1. Absolute neutrophil count &lt;1500 cells/µL&#xD;
&#xD;
               2. Hemoglobin &lt; 9 g/dL&#xD;
&#xD;
               3. Total bilirubin &gt; 1.5 × the upper limit of normal (ULN), with documented liver&#xD;
                  metastases total bilirubin &gt; 3 × the ULN.&#xD;
&#xD;
               4. Aspartate transaminase (AST) and/or alanine transaminase (ALT) &gt; 2.5 × the ULN,&#xD;
                  with documented liver metastases AST and/or ALT levels &gt; 5 × the ULN.&#xD;
&#xD;
               5. Serum creatinine &gt; 1.5 × the ULN, or creatinine clearance &lt; 45 mL/min based on a&#xD;
                  documented 24-hour urine collection or Cockcroft-Gault calculation of glomerular&#xD;
                  filtration rate.&#xD;
&#xD;
               6. International normalized ratio (INR) &gt; 1.5 × the ULN or activated partial&#xD;
                  thromboplastin time (aPTT) &gt; 1.5 × the ULN.&#xD;
&#xD;
             The INR applies only to patients who do not receive therapeutic anti-coagulation.&#xD;
&#xD;
          2. Any anti-cancer therapy, including chemotherapy, hormonal therapy, biologic therapy,&#xD;
             radiotherapy within 4 weeks prior to initiation of study treatment with the following&#xD;
             exceptions:&#xD;
&#xD;
               1. Hormonal therapy with gonadotropin-releasing hormone (GnRH) agonists for prostate&#xD;
                  cancer.&#xD;
&#xD;
               2. Hormone-replacement therapy or oral contraceptives.&#xD;
&#xD;
               3. Palliative radiation to bone metastases &gt; 2 weeks prior to Day 1.&#xD;
&#xD;
          3. Adverse events from prior anti-cancer therapy that have not resolved to NCI CTCAE&#xD;
             Grade ≤ 1, except for alopecia.&#xD;
&#xD;
          4. Prior therapies targeting PARP (poly-ADP ribose polymerase).&#xD;
&#xD;
          5. Clinical significant active infection&#xD;
&#xD;
          6. Known clinically significant history of liver disease, including viral or other&#xD;
             hepatitis, current alcohol abuse, or cirrhosis&#xD;
&#xD;
          7. Known human immunodeficiency virus infection&#xD;
&#xD;
          8. New York Heart Association Class II or greater congestive heart failure; history of&#xD;
             myocardial infarction or unstable angina within 6 months prior to Day 1; history of&#xD;
             stroke or transient ischemic attack within 6 months prior to Day 1&#xD;
&#xD;
          9. Active or untreated brain metastasis&#xD;
&#xD;
         10. Pregnant (positive pregnancy test) or lactating women&#xD;
&#xD;
         11. Male or female patients of child-producing potential unwilling to use double barrier&#xD;
             contraception: condoms, sponge, foams, jellies, diaphragm or intrauterine device,&#xD;
             contraceptives (oral, injectable or parenteral), implanon, or other avoidance of&#xD;
             pregnancy measures during the study and for 90 days after the last day of treatment&#xD;
&#xD;
         12. Inability to take oral medication, prior surgical procedures affecting absorption, or&#xD;
             active peptic ulcer disease&#xD;
&#xD;
         13. Inability to comply with study and follow-up procedures&#xD;
&#xD;
         14. Any other diseases, metabolic dysfunction, physical examination finding, or clinical&#xD;
             laboratory finding that, in the investigator's opinion, gives reasonable suspicion of&#xD;
             a disease or condition that contraindicates the use of an investigational drug or that&#xD;
             may affect the interpretation of the results or renders the patient at high risk from&#xD;
             treatment complications.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BingHe Xu, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>JunNing Cao, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 8, 2018</study_first_submitted>
  <study_first_submitted_qc>April 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2018</study_first_posted>
  <last_update_submitted>March 27, 2021</last_update_submitted>
  <last_update_submitted_qc>March 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Prostate Cancer</keyword>
  <keyword>Advanced solid tumours</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

